Drugs / Quadrivalent Influenza Virus Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02708173 | Mar 2016 | — | Beijing Chaoyang District Centre for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02806804 | May → Jun 2016 | — | Beijing Chaoyang District Centre for Disease Control and Prevention | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00988143 Comparator | Oct → Dec 2009 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Influenza Virus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00988143 ↗ |
| Modality | Vaccine | “prototype Quadrivalent Influenza Vaccine (QIV)” NCT00988143 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT00988143 ↗ |